Effects of Nicotine Replacement and Repeated Cue Exposure on Cigarette Craving
NCT ID: NCT01329614
Last Updated: 2024-03-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
40 participants
INTERVENTIONAL
2009-10-31
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Nicotine Replacement Therapy and D-cycloserine on Nicotine Treatment Seekers
NCT01907594
Combining Noninvasive Brain Stimulation and Cognitive Training on Tobacco Craving
NCT02810574
Effects of Brief Training on Craving Regulation
NCT02153749
A Controlled Laboratory Study of the Effects on Cue-Induced Craving in Dependent Smokers
NCT00901459
Behavioral Therapy for Reduction in Smoking Craving
NCT00449293
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
However, relapse rates remain high even in quitters on the patch. It is thought that cravings related to smoking cues contribute to relapse in smokers on the patch who try to quit. Rational treatment approaches for nicotine dependence therefore include strategies to weaken the effect of smoking cues, e.g. cue extinction training (CET). During CET smokers are repeatedly exposed to smoking cues, in the absence of nicotine administration, and smokers report lessening of cue-induced craving (extinction). It is thought that the extinction of smoking cues will result in less control of the smoking cue over smoking behavior and lower relapse rates.
The investigators hypothesize that smoking quit rates on the patch will be higher after CET. To address our hypothesis the investigators first want to develop a proof of concept procedure that demonstrates that repeated cue exposure in the laboratory results in the lessening or 'extinction' of cue-induced craving. In addition, the investigators are interested in the contribution of nicotine withdrawal to cue-induced craving. To this end, the investigators propose to include a control group without nicotine replacement (i.e. placebo patch) that will also undergo the repeated cue exposure procedure.
This study will assess the effect of CET on subsequent craving triggered by smoking cues in cigarette-smoking volunteers. After overnight abstinence, participants will come into the lab, receive a patch (nicotine or placebo) and undergo the CET procedure and perform computer tests and fill out questionnaires.
The main goal of this project is to study the relationship between nicotine replacement, cue-extinction training and subsequent cue-induced craving. Showing the effectiveness of cue-extinction training in the proposed laboratory model will support the application of the cue-extinction procedure to improve relapse rates of nicotine replacement therapies in future clinical trials.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nicotine Replacement Therapy, 7mg dose
Cue Extinction Training
Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
Nicotine Replacement Therapy
Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.
Cue Extinction Therapy
Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
Progressive Muscle Relaxation
Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
Nicotine Replacement Therapy, 21mg dose
Cue Extinction Training
Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
Nicotine Replacement Therapy
Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.
Cue Extinction Therapy
Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
Progressive Muscle Relaxation
Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
Nicotine Replacement Therapy, Placebo
Cue Extinction Training
Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
Cue Extinction Therapy
Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
Progressive Muscle Relaxation
Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
Nicotine Replacement Therapy, 42mg dose
Cue Extinction Training
Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
Nicotine Replacement Therapy
Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.
Cue Extinction Therapy
Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
Progressive Muscle Relaxation
Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cue Extinction Training
Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
Nicotine Replacement Therapy
Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.
Cue Extinction Therapy
Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
Progressive Muscle Relaxation
Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Not interested in treatment.
* Medically healthy on the basis of physical examination and medical history, vital signs, EKG and laboratory tests, with a negative pregnancy test for females.
* Able to perform study procedures.
* Males or females between the ages of 21-60 years.
* Female participants agree to use an effective method of birth control during the course of the study.
Exclusion Criteria
* Current Axis I diagnosis or current treatment with psychotropic medications (within last 3 months).
* Lifetime history of schizophrenia or other psychotic disorders, bipolar disorder, or anxiety disorders.
* Seeking treatment for nicotine dependence.
* Participants on parole or probation.
* History of significant recent violent behavior.
* Unstable medical condition, Blood Pressure \> 150/90, Pregnancy.
* History of allergic reaction to nicotine patch.
* Participants with significant cardiac history (i.e. angina pectoris, bypass surgery, or coronary artery disease.)
21 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Columbia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
S. Rob Vorel, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Columbia University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New York State Psychiatric Institute - Substance Use Research Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.